Conducted as a multicentric international study involving board-certified veterinary dermatologists, the trial included 35 dogs with CIF in at least two paws.
Each dog acted as its own control, and was treated with systemic antibiotics, with one paw being treated with FLE and the other paw without.
Paws were allocated based on a coin toss, and the study was single blinded: the principal investigator was responsible for the assessment of lesions, and the co-investigator was responsible for administration of FLE treatment.
The dogs were assessed over an 8-week period with check-ups every 14 days.
At every check-up the paws treated with FLE showed a greater improvement than paws without FLE treatment.
The lesions were assessed and scored with the global lesion score, the pruritic visual analogue scale, a cytological scoring, and photographic documentation.
The results of the study demonstrated that FLE combined with systemic antibiotics significantly reduced the time to clinical resolution compared to antibiotics alone.
By week four, 50% of paws in the FLE group had reached clinical resolution compared to 17% in the control group.
By week eight, 88% of paws in the FLE group had healed compared to 54% in the control group.
Dr Anja Lange, DVM, Department of Dermatology, AniCura Kleintierspezialisten Augsburg GmbH, Augsburg, Germany, said: “Canine interdigital furunculosis is a challenging condition to treat that can be prolonged and frustrating.
"Having FLE as an additional management tool is very exciting, not least because it speeds up time to healing, but it also requires us to use less antibiotics.
"The use of FLE was well accepted by all of the dog owners from the study and the dogs themselves tolerated it well, showing it can be a very useful adjunct to cases in clinical practice.”
Reference
Phovia is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
When used together they produce light of varying wavelengths that penetrates the skin to different depths, which Vetoquinol says helps to control bacteria and reduce inflammation on the surface of the skin and stimulates regeneration in the epidermal and dermal layers.
The unit is portable, and applications take four minutes once a week.
After diagnosis and subsequent recommendation by a veterinary surgeon, any trained member of the clinical team can use Phovia.
For the study, which was led by Dr. Andrea Marchegiani, nine female dogs that had undergone unilateral or bilateral mastectomy for mammary neoplasia had half their wounds treated with FLE, whilst the other half served as the control and received no FLE.
To assess the potential benefits of FLE in reducing infection risk, swabs were taken for culture and sensitivity three, five and seven days after surgery.
The swabs from all FLE-managed wound portions showed no bacterial growth, in contrast to the control wounds, in which three dogs had positive culture results.
Andrea said: “For many reasons healing of surgical wounds can become challenging, especially after removal of mammary gland lumps.
"Veterinary clinicians have to face the three-fold challenge of meeting owner expectations of prompt and trouble-free wound healing, recognising those wounds in which healing may be prolonged or impaired and also following the principles of antibiotic stewardship.”
The study concluded that the research underscores the value of Phovia as a significant adjunct to conventional postoperative care in veterinary medicine, offering the dual benefits of reducing potential infection risks and lessening the home care burden for pet owners.
FLE’s application could potentially replace certain topical treatments and improve overall compliance by simplifying the administration of home therapies, thereby relieving pet owners of some responsibilities associated with postoperative care.
https://www.mdpi.com/2076-2615/14/8/1250
Phovia, which was launched in the UK last year, is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
Vetoquinol says that when used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers.
The authors of the Vetoquinol-funded study say that FLE has already been shown to support and accelerate natural skin healing, but this latest research shows that the benefits go beyond improvement in clinical signs.
The study looked at 35 dogs with a diverse range of skin conditions: 13 had interdigital furunculosis, 10 had deep pyoderma, 6 had wounds, 4 had pyotraumatic dermatitis, and 2 had perianal fistula on presentation.
Eight of 35 dogs were new cases, whereas the remaining 27 were undergoing recrudescence of a prior episode, including pyotraumatic dermatitis, wounds, deep pyoderma, interdigital furunculosis and perianal fistulae.
Thirty dogs (86%) achieved a clinical resolution: 18 with the Fluorescent Light Energy alone and 12 with the concomitant use of FLE and topical antiseptic shampoo.
Five dogs (14%) had a partial response and needed other therapies.
92% percent of owners attested to their pet’s enhanced quality of life, with 74% of dogs displaying at least a 50% improvement in owner-reported behaviour, mood, sleep and playing activities.
The study also reported a 46% reduction in caregiver burden.
Felicity Caddick, Technical Services Manager at Vetoquinol said: “Managing skin conditions often requires the long-term use of shampoos or topical therapies.
"Many owners find this aspect of pet ownership challenging, especially with larger dogs, or less cooperative animals.
"FLE can reduce or in some cases eliminate the need for topical therapies at home, not only simplifying the treatment process but also enhancing convenience and compliance.
"Sharing responsibility for administering ongoing treatment with their vet practice also removes some of the worry associated with their pet’s health.”
Vetoquinol also highlights that Phovia can offer vets a drug-free management option for skin disorders that aligns with the principles of antibiotic stewardship.
Felpreva contains emodepside and praziquantel, with tigolaner, a novel bispyrazole active ingredient.
Felpreva is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections.
Vetoquinol points to a survey revealed conducted last year in which 43% of cat owners said that giving parasite protection to their cat makes them feel guilty, stressed, or worried1.
Felpreva provides an option to reduce the frequency of treatments, lessening stressful interactions between owners and their cats.
Vetoquinol says that with Felpreva’s convenience and longer-lasting flea and tick protection, it aims to help support compliance and thus improve the wellbeing of feline companions.
Helen Hunter, Senior Product Manager at Vetoquinol UK, said: “The launch of Felpreva is a truly proud moment for Vetoquinol, demonstrating our expertise, passion, and commitment to innovation in this essential category of companion animal medicine.
"It will allow us to safeguard the health of cats by bringing longer-lasting protection, convenience, and ease of use – for both pet owners and veterinary professionals.
"At a time when vets are treating more pets than ever before, the need for a breakthrough endectocide solution like Felpreva has never been greater.”
Felpreva is in wholesalers now.
For more information, contact your local Vetoquinol representative.
Sponsored by Vetoquinol UK, manufacturers of Cimalgex, the webinar will consider the reasons for switching medications and the pharmacological properties which affect the decision process.
The session aims to better equip vets to make a more informed decision that balances risk of side effects with achieving optimal patient pain management and welfare.
Duncan said: "NSAIDs remain a useful therapeutic tool for pain management in companion animals, particularly for conditions such as canine osteoarthritis.
"Although their benefits are clear at a group level, individual animal response can vary significantly; this is one of the key reasons why a clinician may switch a patient to a different NSAID, but due to concerns around adverse effects this often involves a washout period which can lead to gaps in pain management."
In the webinar, hosted on the WebinarVet platform, Duncan will give an overview of the ‘Whens, Whys and Hows’ of switching NSAIDs in dogs.
This will include findings from scientific studies and recommendations around switching safely, including when the washout period should be observed.
Vetoquinol UK has also put together a free guide for vets on the topic, authored by Dr Lascelles.
Felicity Holford MRCVS, vet and Product Manager at Vetoquinol UK, said: "Vets are prescribing NSAIDs every day, but the existing information around switching and washout periods is limited and can be difficult to apply in practice.
"The webinar and guide will go into the science around the topic and the poster is there to act as a handy prompt for day-to-day use."
Veterinary professionals can register their interest for the webinar here: https://bit.ly/Vetoquinol-WebinarVet
The free NSAID guide and clinic poster are available here: https://bit.ly/NSAID-guide-Vetoquinol
Felpreva is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose.
It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including:
Matthieu Frechin, Vetoquinol CEO, said: “Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.
"It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy.
"We believe that Felpreva will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.”
It is anticipated that Felpreva will be available in Europe early in 2022.
The company initiated the recall after identifying a potential for the sterility/stability of the product to be compromised due to a crimping problem of the aluminium cap.
The recall is for the 100 ml bottles of the following batch only:
Batch No.0C3829 Expiry Date 03/12/2022
Vetoquinol UK Ltd is contacting veterinary surgeons and veterinary wholesalers to examine inventory immediately and quarantine products subject to this recall.
For further information, contact the Customer Services Department on +44 1280 814500 Option 1 or email: UK_office@vetoquinol.com.
The company says the return to a ‘new normal’ post-lockdown provides a significant opportunity for practices to apply a renewed focus to preventative healthcare, recommending parasiticides as a way to improve animal welfare and generate practice revenue, which is vital for economic recovery.
Caitrina Oakes, Vetoquinol Managing Director UK and Ireland, said: “With many pet owners spending more hours than ever with their pets during lockdown, companion animal parasiticides have never been more important – making Profender and Drontal highly relevant in the current environment.”
She added: “It’s a very challenging time for many veterinary practices as everyone adapts to the post-COVID world. I’m looking forward to seeing how the passion and ambition we bring to our brands helps Profender and Drontal to grow and helps us to better serve the needs of the veterinary community, both now and in the future.”
Up to date information on the brands and their distribution can be found on the Vetoquinol website, www.vetoquinol.co.uk, by calling 01280 814500, or practices can contact their Vetoquinol Territory Manager directly.
The company points to research which shows that most dogs and cats whose congestive heart failure is well controlled by medication will have a stable sleeping respiratory rate of less than 30 breaths per minute1,2.
Vetoquinol says SRR is a sensitive indicator of pulmonary oedema or pulmonary effusion which can occur as heart failure patients deteriorate, and that monitoring of SRR is a useful biomarker for veterinary surgeons, allowing you to track progression of congestive heart failure and to detect stability during treatment.
The company also says SRR is most easily detected by the owner when the pet is asleep: using the app to count and record SRR gives clients a good indication of when to seek veterinary intervention and generates data that helps veterinary teams seeking to minimise unnecessary face-to-face contact but still provide emergency care.
While an SRR in the reference range does not exclude heart disease, it reduces the probability that the patient is suffering from left sided heart failure, so may also be a useful measure for remote triage as part of a wider assessment. Other causes of elevated SRR include pain, pneumonia, stress and heatstroke.
Helen Hunter, Product Manager at Vetoquinol and part of the team that developed the app said: "Being able to monitor patients with congestive heart failure is important at any time but during lockdown, with some routine checks having to be postponed, having a means of remote monitoring is more important than ever.
"This tool will help veterinary professionals make the judgement call about whether the pet needs to be seen, especially when the results are provided in the context of monitoring that has taken place over time, providing an assessment of what is normal for that patient."
To complement the addition of the new tool, the site has also launched a webinar delivered by RCVS Recognised Specialist in Cardiology, Dave Dickson of Heart Vets. The presentation discusses the ‘10 Golden Rules of Congestive Heart Failure' and covers topics including the importance of clear radiography and why a cough is not diagnostic of CHF.
Dave said: "Sleeping respiratory rate is one of the most useful ways to monitor an animal in CHF or to look for signs of CHF developing. By encouraging pet owners to monitor and track the dog's sleeping respiratory rate at home, owners can provide vets with a valuable insight into the success of the current treatment regime. The UpLife app is free and will be really helpful to vets and pet owners, both now during lockdown and in the future."
The app can be accessed at www.uplife.uk/srr and it can be communicated to clients at the point when their pet is diagnosed, or shared with clients whose pets already have a diagnosis and are under treatment.
For further information, contact your Vetoquinol Territory Manager, email uk_marketing@vetoquinol.com, or call 01280 814500.
Do you have a question about SRR? Come and ask Dave and other cardiology experts in the VetSurgeon.org Cardiology Expert Forum.
References
The deal is expected to complete by the middle of 2020.
According to the terms of the deal, Vetoquinol will acquire the Profender and Drontal product families, the intellectual property, registrations and other rights currently owned by Bayer AG’s animal health business.
Jeff Simmons, president and CEO of Elanco said: "We’re pleased with the continued progress on a number of fronts to move the acquisition of Bayer AG’s animal health business toward completion.
Matthieu Frechin, CEO of Vetoquinol, said: "We are very pleased to acquire the Profender and Drontal product lines that are highly valued by veterinarians and pet owners. The acquisition of these two strong brands is at the heart of our strategy. On the one hand, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. On the other hand, they will strengthen our portfolio of Essentials, the engine of our growth."
Vétoquinol has announced that Zylkène, a complementary feed used to help pets cope with unpredictable situations, is now available in a 20 capsule pack.
The new packs have been designed to have more 'stand out appeal' on the shelves. Veterinary practices will now be able to display the new packs in waiting rooms and reception areas in a custom-made display unit to generate interest from pet owners and increase revenue for the practice.
Krystyna Joyce, Product Manager at Vétoquinol, said: "This has a huge benefit for the vet practice. As well as increased revenue, pet owners are much more likely to initiate a discussion about behaviour if they can see that there is a product to help their pet adjust to unusual circumstances or environmental changes."
Krystyna added: "With a number of behaviour products on the market, it can be confusing for pet owners to know which ones can be used when. We want to make it easier for pet owners: now when they come to their vets, they can see Zylkène, know what it's for, understand which strength will be right for their pet and pick it up."
As well as increasing product awareness, the packs will work alongside Vétoquinol's ongoing series of pet owner guides which offer advice on how best to help an animal deal with an unusual situation or life change.
Zylkène retail packs are available now from any veterinary wholesaler.
Vétoquinol, manufacturer of Epiphen (phenobarbital), for the control of epilepsy in dogs, has announced the launch of a new starter pack for clients that are embarking on treatment.
The starter packs contain a variety of support materials designed to help owners better understand the condition and its treatment. They sit alongside other support given by the company, which includes an 'Ask the Expert' helpline through which Epiphen veterinary customers can speak to a neurology specialist at The Animal Health Trust in Newmarket, where Vetoquinol sponsors a neurology clinician.
Abbie King, Product Manager for Epiphen, said: ''Our 'Ask the Expert' helpline is a successful service that has been running for several years. 30% of the calls to Vetoquinol's technical team relate to this challenging condition meaning there are few queries our technical team have not tackled before. If extra help is necessary we have an excellent working relationship with The Animal Health Trust and regularly refer cases to them for further advice. We are very proud of this service and are delighted to be able to continue to provide this helpline for our Epiphen clients.''
To use the 'Ask the Expert' service, or order the support materials, ring 0800 1698197. Alternatively visit: www.vetoquinol.co.uk or www.epiphenonline.co.uk.
Vetoquinol - makers of the NSAID Cimalgex - has announced the launch of its updated website www.CiMyDog.co.uk.
The company says the website has been developed to provide reliable online information about pain in dogs to cater for the increasing needs of pet owners and vets.
The website has two sections. The first is a pet owner focussed, educational tool which takes the visitor on a journey through the process of pain; from spotting the signs of pain all the way through to ways of relieving pain, culminating in the recommendation that the visitor seeks advice from their veterinary practice.
The second section requires registration as it contains more in depth information on the pain process and potential treatment options available, this section is for veterinary professionals only. Also on this section of the website there are many scientific abstracts related to pain and treatment with links to enable the veterinary visitor can view this peer reviewed material.
Robert Simpson, Cimalgex Product Manager said: "The internet is a very powerful tool in terms of increasing education, especially in areas such as canine pain. Unfortunately there can also be a lot of misinformation online and so we felt it was important for Vetoquinol to try and redress the balance by producing www.CiMyDog.co.uk. This can be used as a reliable and up-to-date resource by pet owners and veterinary professionals alike. -
www.CiMyDog.co.uk is a very interactive site which aims to demystify the pain treatment process, ensure pet owners look out for behavioural signs of pain and looks to improve overall canine health with assistance from their veterinary practice. We hope that this will be a valuable resource to which vets can refer their pet owners."
Vetoquinol has announced that the vouchers it provides as part of the Epiphen practice support package for monitoring and management of serum levels of phenobarbital will now be provided directly from the veterinary wholesaler and sent with each order.
One or two vouchers are provided with the 30ml and 60ml packs respectively. The vouchers come complete with a pre-paid envelope in which to send samples directly to the laboratory. Each test is valued at £19.80
For further information, contact your local Vetoquinol Territory Manager.
Rimifin (carprofen), an NSAID marketed by Vetoquinol, has been given a new flavour to help increase compliance.
Robert Simpson, Product Manager for Rimifin said: "Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting. The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets."
To find out more about Rimifin please contact your Vetoquinol Territory Manager or call 01280 825424.
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Vetoquinol has announced the launch of Chrysanphyton, the latest addition to its range of Equistro feeding stuffs for horses.
Vetoquinol says Chrysanphyton is recommended for horses where support of a normal blood flow to the hoof is important. It contains Chrysantellum americanum, blackcurrant and hazelnut extracts which, according to the company, provide a rich source of nutrient bioflavanoids and vitamins.
The recommended administration of Chrysanphyton is 10ml twice a day in horses (500kg) and 5ml twice a day in ponies with the 1000ml pack lasting 50 or 100 days respectively.
A product information sheet is available on the Equistro website www.equistro.co.uk
For further information contact your local Vétoquinol Territory Manager.
Vetoquinol has published a waiting room poster which highlights canine pain, to support Cimalgex.
Robert Simpson, Product Manager for Cimalgex said: "This poster aims to highlight that pain may not be obvious to pet owners and that signs which the owner may believe to be age related, for example stiffness, may actually be behavioural signs of pain. The most common sign of pain is a change in behaviour and so this is an area which we believe needs to be highlighted to the pet owner1.
"This new poster uses a strong image to catch the pet owner's attention which, when combined with its simple message, will prompt the pet owner to ask for further information from the veterinary practice regarding pain to ensure the overall wellbeing of their pet. This poster complements our client leaflet in helping the veterinary practice to assist the pet owner to spot signs of pain which may not be very obvious."
To find out more or to request a waiting room poster for your practice please contact your Vetoquinol Territory Manager or call 01280 825424.
1. Hellyer P. et al. AAHA/AAFP Pain Management guidelines for Dogs and Cats. J. AM Anim Hosp Assoc 2007; 43: 235-248.
Vetoquinol has launched a pain monitoring system along similar lines to those used in humans, which can be used by vets and owners to measure pain over time and assess different treatment strategies in dogs.
According to the company, it is widely accepted that all mammals experience pain1and that under treatment is a big issue. Guidelines in treating human pain issued by NICE state that: 'evidence suggests that pain caused by advanced disease remains under-treated'. Veterinary medicine faces a harder task in recognising and treating pain effectively as it relies on behaviour rather than verbal communication.
In human medicine, Client Specific Outcome Measures have been used to assess treatment strategies focussing on identifying the degree of difficulty performing daily tasks on an individual patient to patient basis. Vetoquinol says its pain monitoring system is based on similar principles.
Robert Simpson, Product Manager for Cimalgex said: "The objective assessment of clinical outcomes are a continuing challenge in veterinary medicine; this is particularly true in chronic painful conditions such as osteoarthritis. Use of our Client Specific Outcome Measures form will allow vets and pet owners to more efficiently assess treatment to ensure that the patient is receiving appropriate analgesia.
The form can be adapted to give bespoke outcome measures which are agreed in consultation with the owners. This activity will increase interaction with pet owners and could increase loyalty to the practice; it could also be really useful in geriatric clinics etc as a method of assessing pain outside of consultations in practices."
To find out more or to request a monitoring pad for your practice, contact your Vetoquinol Territory Manager or call 01280 825424.
Vetoquinol UK Ltd has launched a new flea and tick treatment for cats and dogs.
Flevox is a spot-on solution containing fipronil and comes in unique pack sizes of either single pipettes or large clinic packs of 36.
Product Manager Helen Walker said: "With only 55% of pet owners buying their flea and tick treatment from the vet, we recognise there is a huge opportunity to develop and grow this essential market. In the modern age the consumer expects maximum flexibility, and that is what we aim to provide with Flevox.
Whether it be persuading the price-conscious customer away from buying their flea treatments in supermarkets and the internet, or encouraging those who don't treat their pet at all to give it a try without breaking the bank, we're confident we can help grow flea treatment sales in practice."
Vetoquinol says it is supporting the new product with a range of materials dedicated to veterinary surgeries, providing incentives to encourage client bonding and repeat business with your practice.
Helen continued: "We have also teamed up with the fantastic charity Dogs for the Disabled by making a donation for every pipette of Flevox sold. We're really looking forward to raising the profile of this organisation where these amazing dogs give life changing independence to disabled people. We're confident the donation will strike a chord with clients and really engage them with the charity, the Flevox brand and the practice".
To find out more, contact your Vetoquinol territory manager or visit http://www.vetoquinol.co.uk/
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
Vetoquinol has announced that the 50g pack size of Ipakitine will shortly be replaced by a 60g pot.
The company says this will provide the convenience of a 30 day supply for a 5kg cat or dog who is on 1g/5kg bodyweight twice a day (one level scoop twice a day).
The 60g pot will be available from the end of December. Also at this time, the existing 150g size pot will be replaced by a 180g pot.
The new packaging is more eye-catching, easier to read and gives more description. A 300g pot will also be available in February 2012. Pricing will be in-line with increase in pack size, so proportionally a 20% increase for 20% more product.
Ipakitine is a phosphate binder formulated specifically for veterinary use. It is designed for both cats and dogs and is available as a tasteless powder formulation for easy administration with food.
Vetoquinol has announced the launch of Equistro Flexadin UCII, an equine joint supplement.
Equistro Flexadin UCII contains a new ingredient, UC-II, which the company claims is one of the most effective and influential ingredients available that aids and supports healthy joint function.
To celebrate the launch of Flexadin UCII Vetoquinol is offering a £10 money off voucher available through purchases of Horse & Hound magazine starting from November 10th.
Caitríona Mullin, Equine Product Manager at Vetoquinol UK Ltd said: "We are very excited about the launch of Flexadin UCII in the UK and Ireland, we have already received excellent feedback from our German and French colleagues. Flexadin UCII is a product that will further enhance our premium range of equine supplements formulated specifically for the performance horse."
Vetoquinol is launching Forcyl, an injectable anti-infective for the targeted therapeutic treatment of respiratory infections in cattle, in November.
Forcyl is a patented 16% marbofloxacin solution, registered as a single intramuscular injection, which the company says will ensure a high level of compliance.
Forcyl follows the SISAAB concept (single injection short acting antibiotic), with an optimised dosage to minimise the risk of development of antibiotic resistance. Shorter exposure time limits the opportunity for resistance to develop. The formulation means a lower volume of administration (10 ml for 160 kg body weight) is required. Vetoquinol says that other benefits of Forcyl include excellent injection site tolerance and short withdrawal periods (meat: 5 days, milk: 48 hours).
For further information on implementing the SISAAB concept in your practice, please contact one of Vetoquinol's large animal team on 01280 814500.
Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.
Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.
Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.
According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.
Available in a chewable, splitable tablet, Cimalgex can be given with or without food.
Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.
Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.
Reference*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1